Commit Biologics achieves proof-of-concept for novel Complement Engager platform in non-human primates
- Novel approach harnessing the power of the complement system to drive potent cell depletion
- Single-dose study shows rapid and sustained immune cell depletion in blood and tissues with a very favourable safety profile
- Commit Biologics’ CEO Mikkel Wandahl Pedersen to present data at PEGS Europe summit, November 11-13, 2025 in Lisbon, Portugal
Aarhus, Denmark, November 11, 2025 – Commit Biologics (“Commit”), today announced positive results from a non-human primate (NHP) study demonstrating proof-of-concept for its proprietary Complement Engager (BiCE™) platform.
